Query: stroke

Filtered By:
Condition: Heart Failure
Drug: Actos

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research

Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.
CONCLUSIONS: Pioglitazone should be considered in patients with or at high risk of T2DM for the prevention of cardiovascular endpoints, especially in those with a history of established CVD who might benefit the most. Robust reductions in progression of renal disease are seen regardless of baseline renal function degree. PMID: 31822895 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - December 11, 2019 Category: Endocrinology Authors: Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y Tags: J Clin Endocrinol Metab Source Type: research

Activation of The Metabolic Master Regulator PPAR γ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.
The objective is a data-driven approach to set the preclinical and clinical study record straight. The convincing recent clinical trial data on the lack of significant toxicity in high risk populations justify the timely conduction of clinical studies in order to achieve "repurposing" or "repositioning" of pioglitazone for the treatment of clinical PAH. PMID: 31577451 [PubMed - as supplied by publisher]
Source: Am J Respir Cell Mol... - October 2, 2019 Category: Respiratory Medicine Authors: Hansmann G, Calvier L, Risbano MG, Chan SY Tags: Am J Respir Cell Mol Biol Source Type: research

Cardiovascular Protection with Anti-hyperglycemic Agents
AbstractDiabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no effect on reducing macrovascular events like heart attack, stroke, and heart failure. It has been postulated that hypoglycemia may counterbalance some of the beneficial effects of anti-hyperglycemic agents, but this is not proven. Further, trial evidence for thiazolidine...
Source: American Journal of Cardiovascular Drugs - February 15, 2019 Category: Cardiology Source Type: research

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
Conclusions -In IRIS, with surveillance and dose adjustments, pioglitazone did not increase risk of HF, and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. Clinical Trial Registration -URL: www.clinicaltrials.gov Unique identifier: NCT00091949. PMID: 29934374 [PubMed - as supplied by publisher]
Source: Circulation - June 22, 2018 Category: Cardiology Authors: Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone?
The Insulin Resistance Intervention After Stroke (IRIS) trial has reported that treating insulin resistance with the peroxisome proliferator –activated receptor γ agonist pioglitazone hydrochloride reduced recurrent stroke or myocardial infarction (MI) by about one-fourth compared with placebo (pioglitazone, 9.0% vs placebo, 11.8%; hazard ratio [HR], 0.76; 95% CI, 0.62-0.93) in 3876 patients with recent (<6 months) ischemic stroke or transient ischemic attack and insulin resistance but without diabetes, heart failure, or bladder cancer. Pioglitazone was also associated with less incident diabetes vs placebo (3.8% vs ...
Source: JAMA Neurology - November 1, 2017 Category: Neurology Source Type: research

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-yea...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Abstract 013: Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the Iris Trial on Improving Outcomes in Patients With Cerebrovascular Disease Session Title: Poster Session I
Conclusion: In a large US-based outpatient registry, we found that 12% of outpatients with prediabetes or diet-controlled T2D met the main eligibility criteria for IRIS, partly due to the narrow inclusion criteria of the trial but also likely reflective of a general paucity of screening for prediabetes and insulin resistance in this cohort. Pioglitazone was rarely used in these patients but could have a substantial impact on CV outcomes in these eligible patients. The population impact could be even greater if the CV benefit of pioglitazone can be demonstrated in patients with cerebrovascular disease and overt T2D or even ...
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., Kosiborod, M. Tags: Session Title: Poster Session I Source Type: research

Pioglitazone for Secondary Stroke Prevention Clinical Sciences
Conclusions—Pioglitazone reduces recurrent stroke and major vascular events in ischemic stroke patients with insulin resistance, prediabetes, and diabetes mellitus.
Source: Stroke - January 23, 2017 Category: Neurology Authors: Meng Lee, Jeffrey L. Saver, Hung-Wei Liao, Chun-Hsien Lin, Bruce Ovbiagele Tags: Cardiovascular Disease, Diabetes, Type 2, Secondary Prevention, Meta Analysis, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
Conclusions Pioglitazone was associated with reduced risk of MACE in people with insulin resistance, pre-diabetes and diabetes mellitus. However, the risks of heart failure, bone fracture, oedema and weight gain were increased.
Source: BMJ Open - January 5, 2017 Category: Journals (General) Authors: Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., Ovbiagele, B. Tags: Open access, Cardiovascular medicine, Diabetes and Endocrinology Research Source Type: research

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 20, 2016 Category: Consumer Health News Source Type: news

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 19, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Number needed to harm in the post‐marketing safety evaluation: results for rosiglitazone and pioglitazone
ConclusionThe NNH values suggested an increased CV risk with rosiglitazone versus pioglitazone across several sources of information. The inclusion of objective metrics in post‐marketing drug's benefit–risk assessments could be of increased value and help RAs to make consistent decisions on drug safety. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - September 1, 2015 Category: Drugs & Pharmacology Authors: Diogo Mendes, Carlos Alves, Francisco Batel‐Marques Tags: Original Report Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes &amp; Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research

Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity.
Authors: Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenga S Abstract Peroxisome proliferator-activated receptor- (PPAR-) γ expression has been shown in thyroid tissue from patients with thyroiditis or Graves' disease and furthermore in the orbital tissue of patients with Graves' ophthalmopathy (GO), such as in extraocular muscle cells. An increasing body of evidence shows the importance of the (C-X-C motif) receptor 3 (CXCR3) and cognate chemokines (C-X-C motif) ligand (CXCL)9, CXCL10, and CXCL11, in the T helper 1 immune response and in inflammatory diseases such as thyroid autoimmune disorders. PPAR-γ agoni...
Source: PPAR Research - February 28, 2015 Category: Genetics & Stem Cells Tags: PPAR Res Source Type: research